Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 7/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2908859 | 0.85 | FFAR1 (0.64) | FFAR1FFAR4NR4A2TDP1 | |
| SCHEMBL22276673 | 0.83 | TDP1 (0.56) | FFAR1FFAR4TDP1 | |
| SCHEMBL2772855 | 0.80 | FFAR1 (0.83) | FFAR1FFAR4AKR1B1NR4A2THRA | |
| SCHEMBL7276062 | 0.79 | FFAR1 (0.74) | FFAR1FFAR4AKR1B1NR4A2TDP1 | |
| SCHEMBL2223022 | 0.79 | MAOB (0.62) | NR4A2THRB | |
| SCHEMBL1744653 | 0.78 | FFAR1 (1.00) | FFAR1FFAR4AKR1B1 | |
| SCHEMBL1564073 | 0.78 | FFAR1 (0.56) | FFAR1FFAR4AKR1B1NR4A2TDP1 | |
| SCHEMBL9278442 | 0.77 | MAOB (0.61) | NR4A2THRB | |
| SCHEMBL9278438 | 0.77 | MAOB (0.61) | NR4A2THRB | |
| SCHEMBL12087473 | 0.77 | FFAR1 (0.82) | FFAR1FFAR4AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172472-B1 | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor | KYORIN SEIYAKU KK (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-1602660-B1 | AMINOPHOSPHONIC ACID DERIVATIVES, ADDITION SALTS THEREOF AND S1P RECEPTOR MODULATORS | KYORIN SEIYAKU KK (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7759326-B2 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-2172472-A2 | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7456157-B2 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KOHNO YASUSHI | 2008-11-06 | — | — | US | disclosed |
| US-20060160771-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1602660-A1 | AMINOPHOSPHONIC ACID DERIVATIVES, ADDITION SALTS THEREOF AND S1P RECEPTOR MODULATORS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160771-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | S1PR1, S1PR2, S1PR5 | FFAR1 37/4885FFAR4 125/4885AKR1B1 719/4885 |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | S1PR1, S1PR2, S1PR5 | FFAR1 37/4885FFAR4 125/4885AKR1B1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.